Trial Profile

Continuous ReAssessment with Flexible ExTension in Rare Malignancies - CRAFT: the NCT-PMO-1602 Phase II Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary)
Indications Solid tumours
Focus Therapeutic Use
Acronyms CRAFT

Most Recent Events

07 Jan 2025 Status changed from active, no longer recruiting to completed.
11 Dec 2024 Status changed from recruiting to active, no longer recruiting.
24 Oct 2023 Results (n=51) of interim efficacy analysis of ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway actipresented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com